Carine Luxama
Nurse Practitioner · Randolph, MANPI 1114048535
Payments from drug & device makers
Across 113 payments — averaging $36.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$476
- Neurocrine Biosciences, Inc.$337
- Alkermes, Inc.$188
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$183
- Lundbeck LLC$172
- plus $137 from 3 others
What the payments were for
- Consulting fees$1,53037%
- Food & beverage$2,49461%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 47 | $2,621 |
| AbbVie | 30 | $476 |
| Neurocrine Biosciences, Inc. | 10 | $337 |
| Alkermes, Inc. | 6 | $188 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $183 |
| Lundbeck LLC | 8 | $172 |
| Tempus AI, Inc | 1 | $83 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MYCITE$1,530
- ARISTADA$403
- INGREZZA$214
- REXULTI$125
- ABILIFY MAINTENA$109
- ARISTADA INITIO$101
How this compares
$4,113 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 115 | $164,406 |
| IngrezzaValbenazine Tosylate | 16 | $124,462 |
| VraylarCariprazine Hcl | 71 | $120,766 |
| LybalviOlanzapine/Samidorphan Malate | 53 | $85,218 |
| Austedo XrDeutetrabenazine | 14 | $57,361 |
| Oxtellar XrOxcarbazepine | 39 | $24,480 |
| CaplytaLumateperone Tosylate | 15 | $21,792 |
| Clozapine | 150 | $10,929 |
| TrintellixVortioxetine Hydrobromide | 19 | $10,262 |
| Oxcarbazepine ErOxcarbazepine | 12 | $8,405 |
| Olanzapine | 235 | $5,020 |
| Divalproex Sodium ErDivalproex Sodium | 89 | $4,992 |
| Divalproex Sodium | 172 | $4,877 |
| Chlorpromazine Hcl | 20 | $4,844 |
| Duloxetine Hcl | 113 | $4,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,621 | $164,406115 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $337 | $124,46216 claims |
| AbbVieVraylar | $476 | $120,76671 claims |
| Alkermes, Inc.Lybalvi | $188 | $85,21853 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $27 | $57,36114 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $183 | $21,79215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in Randolph
- Alison McManusBoston$346K
- Lauri WelchNorth Chelmsford$110K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Deborah GearySalem$80K
- Amberly ChaplinWorcester$56K
- Darlene MadoreBrockton$42K
- Nancy SydowN Chelmsford$35K
- Miu Lai NgBoston$33K
- Victoria Garcia AlbeaStoneham$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.